Optimizing Inflammatory Bowel Disease Treatment through Biologic Drug Monitoring

 

LabCorp's ​DoseASSURE test portfolio provides tests for both drug concentration (TDM) and anti-drug antibody (immunogenicity)

Inflammatory Bowel Disease (IBD) is a chronic disease impacting nearly 1.2 million Americans.1 Developments in treatment, such as biologics, have greatly improved quality of life for patients and advancements in laboratory testing are helping to support diagnosis and optimize therapy. LabCorp offers leading expertise and comprehensive testing services to support physicians in the management of IBD patients.

Biologics monitoring assays measure both drug concentration and anti-drug antibodies to support improved clinical outcomes and characterize those patients who may have diminished response to therapy.2, 3, 4, 5

DoseASSURE, LabCorp’s portfolio of biologics monitoring assays, may help physicians optimize biological therapy using a personalized, patient-specific approach.

Patient-specific clinical context must be taken into account when evaluating drug and anti-drug antibody. Serial measurements over time may be helpful.

DoseASSURE patient responsibility summary

Patient responsibility is determined by amount billed to patients after the insurance provider has been billed, including copay, coinsurance, deductible, or coverage denials. Based on managed care claim data** from 2018:

The Benefits of DoseASSURE
  • All biologics have variable pharmacokinetics and the potential to induce an antibody-mediated immune response 6,7
  • TDM helps optimize dosing and frequency of treatment 2,7,8
  • TDM assists in preventing and managing loss of response due to immunogenicity9,10
  • TDM has been shown to be cost-effective and may direct more appropriate care.7
  • Most comprehensive portfolio of biologics tested: Infliximab, Infliximab-dyyb, Infliximab-abda, Adalimumab, Vedolizumab, Golimumab, Ustekinumab, Certolizumab

Read our Biologics Q&A

** Based on internal LabCorp billing data (2018).

† Includes claims adjudicated as non-covered and for which there was no patient responsibility indicated by the payer. The explanation of benefits (EOB) from the insurance company explains in detail the services that were either paid or denied. If a claim is denied, the patient is responsible for the amount indicated on the EOB the patient receives from the insurer. If further assistance is needed in determining the reason(s) why the insurance company did not pay for testing, patients should contact their insurance carrier directly. A listing of insurance plans billed by LabCorp can be found at www.labcorp.com.

Want to Speak to your LabCorp Representative?